Discover the most popular tourist attractions in Dubai for 2026. From iconic landmarks and luxury destinations to family-friendly experiences and desert adventures, this complete guide helps visitors explore the very best of Dubai.

Looking for an affordable hotel in Dubai? Learn everything about Premier Inn Al Jaddaf Dubai, including location, facilities, nearby attractions, and why it remains a popular budget-friendly choice in 2026.

Planning a stay at Hyatt Regency Dubai Creek Heights? Explore hotel features, rooms, dining options, location benefits, nearby attractions, and what guests can expect in 2026.

Dubai South is rapidly becoming one of Dubai's most important growth destinations. Discover business opportunities, property developments, infrastructure projects, and investment trends shaping the future of Dubai South in 2026.

Ain Dubai remains one of Dubai's most talked-about attractions. Discover its current status, visitor information, location, experience highlights, and why it continues attracting global attention in 2026

Doc Pharma financial profile: approximately $24 million asset base, approximately $6.7 million in average annual revenue and approximately $3.2 million in average annual gross profit.Immediately accretive: expected to support margin expansion, profitability, and cash flow.Deepens vertical integration: expected to drive synergies, optimized production, economies of scale, expanded capacity, and a strengthened R&D engine.State-of-the-art production plant: GMP-licensed, approximately 59,000 square feet, built to the highest European standards, providing a clear growth avenue.Manufacturing excellence: a broad range of dosage forms, certified to GMP, ISO, Kosher, and Halal standards, with site registrations for the UAE, Qatar, Iraq and Lebanon.Boosts product portfolio: adds advanced and branded generics and OTC pharmaceutical products to the Cosmos Health portfolio. CHICAGO, June 11, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ('Cosmos Health' or the 'Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has entered into a non-binding letter of intent (the 'LOI') to acquire 100% of Doc Pharma S.A. ('Doc Pharma'), a fully licensed GMP pharmaceutical manufacturer.